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ABSTRACT
Machine learning techniques for cancer prediction and biomarker discovery can
hasten cancer detection and significantly improve prognosis. Recent “OMICS” studies
which include a variety of cancer and normal tissue samples along with machine
learning approaches have the potential to further accelerate such discovery. To
demonstrate this potential, 2,175 gene expression samples from nine tissue types
were obtained to identify gene sets whose expression is characteristic of each cancer
class. Using random forests classification and ten-fold cross-validation, we developed
nine single-tissue classifiers, two multi-tissue cancer-versus-normal classifiers, and
one multi-tissue normal classifier. Given a sample of a specified tissue type, the
single-tissue models classified samples as cancer or normal with a testing accuracy
between 85.29% and 100%. Given a sample of non-specific tissue type, the multitissue bi-class model classified the sample as cancer versus normal with a testing
accuracy of 97.89%. Given a sample of non-specific tissue type, the multi-tissue multiclass model classified the sample as cancer versus normal and as a specific tissue type
with a testing accuracy of 97.43%. Given a normal sample of any of the nine tissue
types, the multi-tissue normal model classified the sample as a particular tissue type
with a testing accuracy of 97.35%. The machine learning classifiers developed in this
study identify potential cancer biomarkers with sensitivity and specificity that exceed
those of existing biomarkers and pointed to pathways that are critical to tissuespecific tumor development. This study demonstrates the feasibility of predicting the
tissue origin of carcinoma in the context of multiple cancer classes.

INTRODUCTION

The identification of cancer-specific biomarkers is
being evaluated as an alternative diagnostic and treatment
option since it is minimally invasive and thus has the
potential to lower the cost of diagnosis. Already, several
biomarkers have been identified and used to some extent
in diagnosis; however, they usually have low accuracy,
selectivity, and specificity, and high false-positive, falsenegative rates of diagnosis [2]. Therefore, improving the
process and tools for the discovery of new biomarkers is
essential for future improvement in cancer diagnostics and
successful treatment.
While many strategies for discovering biomarkers
exist, selecting useful biomarkers is a challenging
task [3, 4]. Examples of these strategies include
gene-expression profiling, mass-spectrometry-based

Cancer has been characterized as a heterogeneous
disease that is categorized by many different types and
subtypes. In the United States, cancer is the second leading
cause of death. In 2016, over 1.6 million new cases of
cancer were diagnosed and over 600,000 people died from
this disease; the disease accounts for approximately 23%
of all deaths in the US each year [1]. Successful treatment
depends on the timely diagnosis, and the five-year survival
rate significantly increases with early detection. Diagnosis
typically begins with symptomology, is supported by
imaging technology, and is confirmed histopathologically
by biopsy. These methods, however, suffer from low
sensitivity and high costs.
www.impactjournals.com/oncotarget
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RESULTS

proteomic profiling, protein arrays and secreted protein
approach [5]. Genomic and proteomic technologies
have increased the number of potential biomarkers
under investigation [6]. Furthermore, analysis of a
single biomarker or a combination of only a few is
increasingly being replaced by multiparametric analysis
of genes, RNA, or proteins [7–10]. Specifically, highthroughput techniques such as microarrays and several
machine-learning methods have been developed to
study cancer classification and discovery of potential
biomarkers [6, 11–20].
Many conventional biomarkers were established
via discriminant analysis, through the comparison
of cancerous tissues with normal tissues [21] or
identifying nuanced differences among cancer subtypes
[22, 23]. Progress in cancer biomarker identification has
come through the application of machine learning to
the analysis of high-throughput data from microarrays
[24–29]. However, challenges remain in the application
of machine learning to analyze biomarker data due to
small sample sizes, the sheer size, and complexity of
each dataset, as well as the diversity of experimental
design [30].
The biomarker identification strategy outlined in this
paper involves selecting genes whose differential expression
in building cell structure, maintaining homeostasis, or the
progression of cancer is a discriminating factor [31–34]. To
achieve this, we developed single-tissue and multi-tissue
machine learning cancer-versus-normal-classifiers using
gene expression data that were used to identify tissuespecific cancer biomarkers. These biomarkers were obtained
from machine learning models using gene expression
data obtained and normalized from 2,175 samples and
span nine tissue types. A feature selection method was
identified to select informative genes (predicted biomarkers)
from preprocessed data. Machine-learning models were
identified through the analysis of gene expression samples
from human cancer and non-cancerous tissue types that
accurately distinguish malignant tissue from normal tissue
and different malignant tissue types from each other.
Using functional characterization and pathway analysis,
the known tissue-specific cancer-related pathways were
validated, and novel cancer-related pathways and functional
groups for each of the tissue-specific predicted biomarkers
were identified. The diagnostic capacity of the biomarkers
predicted by the methods in this study (and later assessed by
comparing their sensitivity and specificity to the sensitivity
and specificity of known biomarkers for all tissue types)
showed significant improvements over existing biomarkers.
The development of our cancer prediction models and
identification of the potential biomarkers may facilitate
accurate, unbiased cancer diagnosis and effective treatment,
ultimately improving cancer prognoses. Furthermore, the
gene-expression signatures discovered by this classification
approach may lead to new clinical reagents for successful
tumor diagnosis.
www.impactjournals.com/oncotarget

Identification of the best feature selection
algorithm
Of all the combinations of feature selection
algorithms and feature thresholds tested (Step 4 in
Figure 1), the Filtered Attribute Evaluator with Ranker
method (FAER) used with a feature threshold of the top
1% genes performed the best (Supplementary Figure 1
shows the workflow for identification of the best feature
selection algorithm and Supplementary File 1 provide the
performance details of the feature selection algorithms;
see Methods for the list of feature selection algorithms
and feature thresholds). As such, FAER with a feature
threshold of 1% was used for feature selection throughout
this study.

Predictive power of the models
Single-tissue models
Given a sample of a specific tissue type, singletissue models accurately classify the sample as cancer or
normal. Each single-tissue model more accurately classified
samples from the same tissue type (same-tissue) than it
classified samples from other tissue types (across-tissues).
The area under the ROC (receiver operating characteristics)
curve for tissue-specific models ranged from 0.84 (Colon
model) to 1 and is shown in Figure 2. Same-tissue testing
accuracies ranged from 85.29% (Tongue Model) to 100%
(Blood, Head and Neck and Lung Models). Across-tissues
test accuracies ranged from 33.46% (Lung Model) to
88.68% (Gastric Model). (More details can be found in
Supplementary Figure 2 and Supplementary Table 1).
Among the two classifiers, the random-forests
classifier performed better than the Support Vector
Machine classifier for each model except the Tongue
model (the Random Forests classifier yielded an 85.29%
same-tissue testing accuracy compared to 94.11% by the
Support Vector Machine classifier). The Random Forests
classifier outperformed the Support Vector Machine
classifier in the across-tissues testing accuracies for each
model. Supplementary Figure 3A and 3B show the sametissue and across-tissues accuracies respectively. (To see
differences between the performances of these classifiers,
see Supplementary Table 2 and Supplementary Table 3).
As a result, the models were constructed with Random
Forests for the duration of this study.
A list of 244 genes (predicted biomarkers) was
identified for each tissue type (See Supplementary File 2 for
complete list of biomarkers for each tissue type and Table 2
for the number of characterized and uncharacterized genes
for each tissue type) is given in Supplementary File 3
whereas, the list of uncharacterized genes is provided in
Table 3.
85693
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Multi-tissue bi-class model

multi-tissue multi-class models achieved training and
testing accuracies of 96.96% and 97.43%, respectively.
The precision, recall, and F1- score for these models
varied among classes (Figure 4). For the following
classes, the model had 100% precision using the training
dataset: blood-tumor, blood-normal, breast-tumor, gastrictumor, gastric-normal, and head and neck-tumor. For the
following classes, the model had 100% recall using the
training dataset: blood-normal, gastric-normal, head-and
neck-tumor, head-and-neck normal, lung-tumor, lungnormal, and tongue-normal. Out of all the classes, colonnormal (precision: 33.33%), prostate-normal (precision:
33.33%), and tongue-normal (precision: 28.57%) had
the lowest precision using the training dataset (See
Supplementary Table 4–6 for precision, recall, F1-score
and confusion matrices).

Given a sample of any of nine tissue types, the
multi-tissue bi-class model accurately classifies the sample
as cancer or normal. The area under the ROC curve for the
multi-tissue bi-class model is 0.88 and is shown in Figure
3A. The multi-tissue bi-class model achieved training and
testing accuracies of 97.33% and 97.89%, respectively.
The model was more accurate in predicting a Cancer
sample (Precision and Recall of 98.95% and 97.70%,
respectively) than a Normal sample (Precision and Recall
of 91.27% and 95.87%, respectively). (See Table 1 for
Precision, Recall, and F1- score measures for both training
and testing datasets.)
Multi-tissue multi-class model
Given a sample of any of the nine tissue types, the
multi-tissue multi-class model accurately classifies the
sample as cancer or normal, and as of a specific tissue
type. The area under the ROC curve for the multi-tissue
multi-class model is 0.97 and is shown in Figure 3B. The

Multi-tissue normal multi-class model
Given a normal sample of any of the nine tissue
types, the multi-tissue normal multi-class model accurately

Figure 1: Schematic representation of the study workflow for each model. (1) Microarray gene expression data for each tissue

type relevant to the model were collected from the NCBI Gene Expression Omnibus (GEO) repository. (2) The data were then normalized,
and background correction was performed on these data. (3) The preprocessed data were then partitioned into training and testing sets. (4)
Feature selection was conducted on the training dataset to extract the list of important genes. (5) The list of selected genes was then mapped
to the training data to generate the feature vectors using a process called Dimensionality Reduction. (6) Feature vectors were trained to
create multiple models. (7) Ten-fold cross-validation was used to identify the optimal model. (8) The model performance was assessed by
the testing its accuracy using the testing dataset. (9) The model was used to predict the class labels for the samples in the unknown dataset.
(10) The functional analysis was performed using the selected genes to retrieve the pathways and functional groups.
www.impactjournals.com/oncotarget
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Table 1: Precision, recall and F1-Score for the multi-tissue bi-class model for training and testing
data
Class of
Samples

# of Tumor
Samples

Tumor
Normal

849
20

Training
# of
Precision Recall
Normal
(%)
(%)
Samples
9
98.95
97.70
209
91.27
95.87

Testing
F1Score
98.32
93.513

classifies the sample as of a particular tissue type. The area
under the ROC curve for the multi-tissue normal multiclass model is 0.95 and is shown in Figure 3C. The multitissue normal multi-class models achieved training and
testing accuracies of 97.88% and 97.35%, respectively.
The models’ precision and recall for each normal class
using the testing dataset ranged from 87.5% to 100%,
and from 95.45% to 100%, respectively (See Figure 5,
Supplementary Tables 7–9 for details).

# of
Tumor
Samples
854
19

# of
Normal
Samples
4
211

Precision Recall
(%)
(%)
99.53
91.74

97.82
98.14

F1Score
98.67
94.83

pathways (Figures 6-8, Supplementary Figures 4–6, and
Supplementary File 4).
Significant pathways for each tissue type are
presented below.
Blood
Four pathways were identified using blood tissue
genes. The only metabolic pathway identified was hsa00564:
glycerophospholipid metabolism. The other three pathways
are involved in intracellular signaling: hsa04015: Rap1
signaling pathway, hsa04064: NF-kappa B signaling pathway
and hsa04080: neuroactive ligand-receptor interaction.

Functional analysis

Breast

Enrichment of cancer tissue-specific genes in metabolic
and signaling pathways

Six pathways were identified using the breast tissue
genes. Some of these pathways are involved in interor intra-cellular structures: hsa04510: focal adhesion
and hsa04810: regulation of the actin cytoskeleton.
The rest were signaling motifs: hsa04670: leukocyte
transendothelial migration, hsa03010: ribosome and
hsa05131: shigellosis pathway.

A total of 104 KEGG (Kyoto Encyclopedia of
Genes and Genomes, [35]) pathways were identified for
the nine tissue types. The gastric tissue genes had the
most pathways (38), whereas the blood and lung tissue
genes had the fewest pathways (4). The colon-tissue
genes had the second highest number (14) of KEGG

Figure 2: ROC for single-tissue specific models. The area under the ROC curves is shown for each model. (A) Breast, (B) Colon,
(C) Gastric, (D) Prostate, (E) Thyroid, and (F) Tongue. The ROC for the Blood, Head & Neck and Lung models are not shown due to the
due to their AUC = 1.
www.impactjournals.com/oncotarget
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Table 2: Distribution of characterized and uncharacterized genes for each tissue type
Tissue
Blood
Breast
Colon
Gastric
Head & Neck
Lung
Prostate
Thyroid
Tongue

Predicted Biomarkers
(Characterized Genes)
170
239
240
238
243
224
238
240
237

Colon

Predicted Biomarkers
(Uncharacterized Genes)
74
5
4
6
1
20
6
4
7
interconversions, hsa00140: steroid hormone biosynthesis,
hsa00860: porphyrin and chlorophyll metabolism,
hsa00980: metabolism of xenobiotics by cytochrome P450
(For detailed results, refer to the Supplementary File 4).

Colon tissue genes were used to identify 14 pathways.
One of this pathways was a signaling pathway: hsa04725:
cholinergic synapse. Another pathway was involved in
disease development, hsa05204: chemical carcinogenesis.
Most of the remaining pathways were involved in diverse
metabolic functions: hsa00830: retinol metabolism,
hsa00982: drug metabolism–cytochrome P450, hsa00983:
drug metabolism–other enzymes, hsa00053: ascorbate and
aldarate metabolism, hsa00040: pentose and glucuronate

Gastric
Gastric tissue genes were used to identify 38
pathways. Many of the pathways were involved in
synaptic function: hsa04724: glutamatergic synapse,
hsa04727: GABAergic synapse, hsa04725: cholinergic
synapse, hsa04728: dopaminergic synapse, hsa04726:

Figure 3: ROC for multi-tissue models. The area under the ROC curves is shown for each model. (A) multi-tissue bi-class model,
(B) multi-tissue multi-class model, (C) multi-tissue normal multi-class model.
www.impactjournals.com/oncotarget
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Head and neck

serotonergic synapse. Other pathways were involved in the
different signaling aparati (hsa04062: chemokine signaling
pathway, hsa04014: ras signaling pathway, hsa04070:
phosphatidylinositol signaling system, hsa04151: PI3KAkt signaling, hsa04071: sphingolipid signaling, hsa04744:
phototransduction, and hsa04022: cGMP-PKG signaling
pathway). The disease-related pathways included hsa05200:
pathways in cancer, hsa05034: alcoholism, hsa05142:
Chagas disease, hsa05146: amoebiasis, hsa04930: type
II diabetes mellitus, hsa05213: endometrial cancer. The
remaining pathways are involved in various forms of
fatty acid chain metabolism: hsa00562: inositol phosphate
metabolism, hsa00564: glycerophospholipid metabolism,
hsa00592: alpha-Linolenic acid metabolism, hsa00565: ether
lipid metabolism, hsa00563: glycosylphosphatidylinositol
(GPI)-anchor biosynthesis, hsa00590: arachidonic acid
metabolism (Supplementary File 4).

Using the Head and Neck tissue genes we identified
ten pathways. Most of these pathways are specific to
cellular signaling and regulation of signaling pathways:
hsa04015: Rap1 signaling, hsa04610: complement and
coagulation cascades, hsa04550: signaling pathways
regulating pluripotency of stem cells, hsa04014: Ras
signaling, hsa04151: PI3K-Akt signaling and has03018:
RNA degradation. The disease-related pathways involve
hsa05150: Staphylococcus aureus infection, hsa05218:
melanoma, hsa05200: pathways in cancer, and hsa05217:
Basal cell carcinoma.
Lung
Four pathways were identified using lung tissue
genes. Three of these pathways were involved in signal
transduction: hsa04080: neuroactive ligand-receptor

Figure 4: Performance of the multi-tissue multi-class models for each class. (A) Precision and recall using the training dataset.
(B) Precision and recall using the testing dataset.

Figure 5: Performance of the multi-tissue normal multi-class model for each class. Precision and Recall values are shown for
each of the nine tissue types using the testing dataset.
www.impactjournals.com/oncotarget
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Table 3: List of uncharacterized genes predicted as biomarkers from different tissue types
Potential Biomarker (Uncharacterized genes)

Tissue

CTC-265F19.1

Blood

CTC-360P9.3

Blood

CTC-378H22.2

Blood

CTC-384G19.1

Blood

CTC-400I9.1

Blood

CTC-428G20.6

Blood

CTC-436K13.5

Blood

CTC-459F4.3

Blood

CTC-462L7.1

Blood

CTC-471C19.1

Blood

CTC-471F3.6

Blood

CTC-471J1.2

Blood

CTC-527H23.4

Blood

CTC-550B14.7

Blood

CTD-2002J20.1

Blood

CTD-2008P7.1

Blood

CTD-2012K14.6

Blood

CTD-2021H9.3

Blood

CTD-2033C11.1

Blood

CTD-2035E11.5

Blood

CTD-2036P10.3

Blood

CTD-2076M15.1

Blood

CTD-2083E4.4

Blood

CTD-2083E4.7

Blood

CTD-2118P12.1

Blood

CTD-2130O13.1

Blood

CTD-2196E14.6

Blood

CTD-2199O4.3

Blood

CTD-2199O4.7

Blood

CTD-2251F13.1

Blood

CTD-2256P15.2

Blood

CTD-2269F5.1

Blood

CTD-2281E23.2

Blood

CTD-2284J15.1

Blood

CTD-2286N8.2

Blood

CTD-2287O16.5

Blood

CTD-2293H3.1

Blood

CTD-2302E22.4

Blood

CTD-2310F14.1

Blood

CTD-2311B13.7

Blood

CTD-2313J17.5

Blood

CTD-2314B22.3

Blood

CTD-2325A15.5

Blood

CTD-2366F13.2

Blood

CTD-2373J6.1

Blood

CTD-2377D24.6

Blood

CTD-2520I13.1

Blood

CTD-2534I21.8

Blood

CTD-2537I9.16

Blood

CTD-2537I9.5

Blood

CTD-2540F13.2

Blood

CTD-2541J13.1

Blood

CTD-2541M15.1

Blood

CTD-2542L18.1

Blood

CTD-2547L24.4

Blood

CTD-2553C6.1

Blood

CTD-2554C21.3

Blood

CTD-2555O16.4

Blood

CTD-2561B21.11

Blood

CTD-2587H24.10

Blood

CTD-2587M23.1

Blood

CTD-2611O12.6

Blood

CTD-2616J11.10

Blood

CTD-2619J13.13

Blood
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CTD-2619J13.17

Blood

CTD-2639E6.4

Blood

CTD-2647L4.1

Blood

CTD-3028N15.1

Blood

CTD-3046C4.1

Blood

LOC730139

Blood

LOC731424

Blood

LOC80154

Blood

LOC90834

Blood

LQFBS-1

Blood

AX746733

Breast

RP11-114H24.6

Breast

RP11-255C15.3

Breast

RP11-348B17.1

Breast

RP11-403P17.4

Breast

LA16C-381G6.1

Colon

LOC100652770

Colon

RP11-295M18.6

Colon

RP11-38P22.2

Colon

GS1-103B18.1

Gastric

GS1-111G14.1

Gastric

GS1-18A18.2

Gastric

GS1-124K5.9

Gastric

GS1-164F24.1

Gastric

GS1-304P7.2

Gastric

FLJ11292

Head And Neck

RP11-69I8.2

Lung

RP3-406C18.2

Lung

RP4-710M16.1

Lung

AC007967.3

Lung

LOC613037

Lung

LOC100127886

Lung

RP1-217P22.2

Lung

AC009947.3

Lung

RP11-770J1.4

Lung

RP11-209A2.1

Lung

RP5-1184F4.5

Lung

MGC13053

Lung

RP3-391O22.2

Lung

LOC649330

Lung

RP3-406P24.1

Lung

RP13-258O15.1

Lung

RP5-1118D24.2

Lung

GS1-124K5.9

Lung

RP1-190J20.2

Lung

RP1-192P9.1

Lung

AC004941.5

Prostate

LOC100506119

Prostate

RP1-101G11.2

Prostate

RP11-297L17.2

Prostate

AX746823

Prostate

RP11-96K19.4

Prostate

RP6-24A23.7

Thyroid

LOC100506558

Thyroid

LOC101930400

Thyroid

LOC102725271

Thyroid

CTA-384D8.35

Tongue

RP11-353N14.2

Tongue

CTC-444N24.11

Tongue

RP11-539I5.1

Tongue

LOC101928615

Tongue

GS1-111G14.1

Tongue

RP11-250B2.3

Tongue
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Enrichment of cancer tissue-specific genes in various
functional groups

interaction, hsa04024: cAMP signaling, and hsa04924:
renin secretion. The fourth pathway is involved in
hsa04260: cardiac muscle contraction.

Using tissue-specific genes, functional groups
were identified related to protein kinase inhibitor activity
(GO:0004860), negative regulation of JAK-STAT cascade
(GO:0046426), myosin complex (GO:0016459), G-protein
coupled receptor signaling pathway (GO:0007186),
GTPase activity (GO:0003924), signal transducer activity
(GO:0004871), flavone metabolic process (GO:0051552),
tissue homeostasis (GO:0001894), amino acid transmembrane
transporter activity (GO:0015171), regulation of MAPK
cascade (GO:0043408), type I interferon signaling pathway
(GO:0060337), and others. Figures 9–11 show the
functional groups with the top five Gene Ontology (GO)
groups with the total number of genes from each tissuespecific gene list. See Supplementary File 5 for full list of
functional groups.

Prostate
Prostate tissue genes were used to identify eight
pathways. These include several metabolic pathways:
hsa00480: glutathione metabolism, hsa00051: fructose
and mannose metabolism, hsa00982: drug metabolism–
cytochrome P450, hsa00030: pentose phosphate pathway
and hsa00052: galactose metabolism. The other pathways
are hsa04512: ECM-receptor interaction signaling
pathway, hsa05200: pathways in cancer, and hsa04510:
focal adhesion, a structural pathway.
Thyroid
Nine pathways were identified using thyroid tissue
genes. The signaling pathways included hsa04512: ECMreceptor interaction and hsa04151: PI3K-Akt signaling. A
few structural pathways were identified, including hsa04510:
Focal adhesion, hsa05205: proteoglycans in cancer and
hsa04360: axon guidance. The only metabolic pathway
identified was hsa00350: tyrosine metabolism. The diseaserelated pathways include hsa05222: small cell lung cancer,
hsa05200: pathways in cancer, and hsa05146: amoebiasis.

Predicted biomarkers perform better than existing
biomarkers
A total of 244 potential biomarkers were identified for
each tissue type distributed across the different cancer types
(Supplementary File 2). The quality of these predictions
was assessed by comparing the sensitivity and specificity
of biomarkers to the sensitivity and specificity of existing
biomarkers collected from the literature (Supplementary
Tables 10–16). Biomarkers predicted by our machine learning
models resulted in higher sensitivity and specificity for each
tissue type than those of existing biomarkers (Figure 12).

Tongue
Twelve pathways were identified using tonguetissue genes. Many of the identified pathways were
disease-related, including hsa05323: rheumatoid arthritis,
hsa05146: amoebiasis, hsa05200: pathways in cancer,
hsa05142: Chagas disease, hsa05132: Salmonella
infection, hsa05222: small cell lung cancer, and hsa05140:
leishmaniasis. The only structural pathway was hsa05205:
proteoglycans in cancer. The following four signaling
pathways were hsa04620: Toll-like receptor signaling,
hsa04062: chemokine signaling, hsa04512: ECM-receptor
interaction, and hsa04060: cytokine-cytokine receptor
interaction.

DISCUSSION
In this study, machine learning models were
developed to analyze a large-scale human gene-expression
dataset to identify cancer biomarkers within nine tissue
types. Given the presence of cancer, machine learning
models were also equipped to distinguish between cancer
types. A machine-learning method to select informative

Figure 6: Number of significant pathways for the genes (predicted biomarkers) from each tissue type. A pathway was
significant if its p-value was less than or equal to 0.05 and it had a minimum of three tissue-specific genes.
www.impactjournals.com/oncotarget
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Figure 7: KEGG Pathway mapping for each tissue type using identified genes (potential biomarkers). A pathway was
considered significant if its p-value was less than or equal to 0.05 and it had a minimum of three tissue-specific genes.
www.impactjournals.com/oncotarget
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Figure 8: Number of selected genes (potential biomarkers) in pathways for each tissue type. A pathway was considered
significant if its p-value was less than or equal to 0.05 and it had a minimum of three tissue-specific genes.
www.impactjournals.com/oncotarget
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Figure 9: Top five significant Gene Ontology groups with the total number of predicted tissue genes. A functional group
was considered significant if its p-value was less than or equal to 0.05 and if it had a minimum of three tissue-specific genes. (A) Blood,
(B) Breast, (C) Colon, (D) Gastric

Figure 10: Top five significant Gene Ontology groups with the total number of predicted tissue genes. A functional group
was considered significant if its p-value was less than or equal to 0.05 and it had a minimum of three tissue-specific genes. (A) Head &
neck, (B) Lung, (C) Prostate, (D) Thyroid
www.impactjournals.com/oncotarget

85703

Oncotarget

Machine learning methodology

genes (potential biomarkers) was identified for each tissue
type. Four different classifiers were developed: (1) models
which, given a sample of a specific tissue type, accurately
classify the sample as cancer or normal (“single-tissue”),
(2) a model which, given a sample of any of nine tissue
types, accurately classifies the sample as cancer or normal
(“multi-tissue bi-class”), (3) a model which, given a
sample of any of the nine tissue types, accurately classifies
the sample as cancer or normal, and as of a specific tissue
type (“multi-tissue multi-class”), and (4) a model which,
given a normal sample of any of the nine tissue types,
accurately classifies the sample as of a particular tissue
type (multi-tissue normal multi-class). (See Figure 13A
and Supplementary Table 17 for distribution of samples
among tissue types.) The classifiers, trained to incorporate
a vast array of different tissue types, and the predicted
biomarkers may facilitate accurate, unbiased cancer
diagnosis and effective treatment, ultimately improving
prognoses.

The selection of relevant genes involved in
different types of cancer remains a challenge [36, 37].
Moreover, for diagnostic purposes, it is important to find
a small subset of genes that are sufficiently informative
to distinguish between different cancer types. To extract
useful gene information from cancer microarray data and
reduce dimensionality, feature-selection algorithms were
systematically investigated in this study. To this end, a
feature selection method was identified (FAER with 1%
feature threshold) from twelve feature selection algorithms
to select informative genes (potential biomarkers) for
each tissue type. As we showed, selecting relatively small
subsets of genes significantly improved the performance
of our classification models. The single-tissue models
were tested using the testing data from all the nine tissues
as part of the negative control. Each single-tissue model
more accurately classified samples from the same tissue

Figure 11: Top five significant Gene Ontology groups with the total number of predicted tongue tissue genes. A functional
group was considered significant if its p-value was less than or equal to 0.05 and if it had a minimum of three tissue-specific genes.

Figure 12: Performance of predicted biomarkers with known biomarkers for each tissue type. (A) Sensitivity of the

existing biomarkers (breast: 50.1%, colon:63%, gastric:87.95%, head&neck:60%, lung:85%; prostate:67%, tongue:79%) is represented by
box plot (blue) and sensitivity of our predicted biomarkers (breast:100%, colon:97.92%, gastric: 99.37 %, head & neck:100%, lung:100%;
prostate:100%, tongue:96.3%) is represented by cross mark (orange). (B) specificity of the existing biomarkers (breast:66.89%, colon:90%,
gastric: 90.3%, head& neck:92.9%, lung:82%; prostate:70%, tongue:80%) is represented by box plot (blue) and specificity of our predicted
biomarkers (breast:98.46%, colon: 100%, gastric: 100%, head & neck:100%, lung:100%; prostate:95%, tongue:86.67%) is represented by
cross (orange).
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type (same-tissue) than it did samples from other tissue
types (across-tissues). The multi-tissue bi-class and multiclass models were not only able to classify the sample as
cancer or normal but also the tissue of origin. Moreover,
this feature selection process also identified genes that are
closely related to the pathways and functional groups of
various cancers.

implications for colon cancer [45]. Some colon cancer
genes also identified include metabolism of xenobiotics;
biotransformation of xenobiotics occurs in the human
colon and rectum, and it is known to be associated with
colorectal cancer [46–48]. Pentose and glucuronate
interconversions were also identified using colon-tissue
genes. The heightened metabolic demands of colon cancer
cells are known to result in increased glucose uptake and
glycolytic flux relative to normal tissues [49, 50]. One
common feature of the altered metabolism in cancer is
the increased glucose uptake and fermentation of glucose
to lactate, a phenomenon known as the Warburg Effect
[51, 52]. In tumor cells and other proliferating cells, the
rate of glucose uptake dramatically increases, even in the
presence of oxygen and fully functioning mitochondria.

Metabolic pathways
The metabolism of a tumor depends on both the
genotype and tissue of origin and has implications regarding
the design of therapies targeting tumor metabolism [38].
Tissue-specific genes pointed to metabolic pathways that
may be critical to tumor development in general and tissuespecific tumor development (see the list of pathways in
Supplementary File 4). Metabolic rewiring is essential
for the progression of many types of cancer [39, 40]. We
discuss the metabolic pathways for selected tissues below.

Gastric
Many of the pathways identified using gastric
tissue genes are involved in various forms of fatty acid
chain metabolism: inositol phosphate metabolism,
glycerophospholipid metabolism, ether lipid metabolism,
glycosylphosphatidylinositol (GPI)-anchor biosynthesis,
arachidonic acid metabolism and alpha-Linolenic acid
metabolism. α-linolenic acid is known be the most
effective in suppressing the growth of gastric cancer
cells [53]. These results suggest that the metabolism of
fatty acids may play a critical role in the tumorigenesis
of gastric cancer. Levels of metabolism of fatty acids in
cancer cells are known to vary across tissue types [54].

Blood
The metabolic pathway identified using the blood
tissue genes is glycerophospholipid metabolism, and
there is an increase of acyl-glycerophospholipids in acute
myeloid leukemia [41].
Colon
Most of the metabolic pathways identified using the
colon tissue genes have known links to colon cancer. One
such pathway is retinol metabolism; retinoids are known
to play a role in the prevention and treatment of colorectal
cancer [42–44]. Some of the colon-cancer genes identified
also include steroid hormone biosynthesis, as the bacterial
cells in the gut produce steroid hormones that can have

Prostate
Some of the metabolic pathways identified using the
prostate tissue genes are glutathione metabolism and pentose
phosphate metabolism. The glutathione S-transferases

Figure 13: Sample Distribution of Tumor and Normal samples by tissue of origin. (A) Distribution of Tumor and Normal

samples (2175) by tissue of origin. (B) Distribution of Tumor (1716) samples by tissue of origin. (C) Distribution of Normal (459) samples
by tissue of origin.
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(GSTs) enzymes are known to be involved in the metabolism
of numerous potential prostate carcinogens [55, 56]. Cancer
cells display an increased demand for glucose. Clinical data
suggested that the glucose-6-phosphate dehydrogenase
(G6PD), the rate-limiting enzyme in the pentose phosphate
pathway, is upregulated in prostate cancer [57].

from one or more of the following: immune suppression,
chronic inflammation, and dysregulated inflammation
[78–80]. Many of these infectious disease-related pathways
were found using the tissue-specific genes identified in
this study. For example, the Staphylococcus aureus (gram
positive bacteria) pathway was found using head and neck
genes. Staphylococcus aureus is known to be present in oral
squamous-cell carcinoma tissue [81] and is also abundant
in the blood of oral cancer patients [82]. The infectious
disease-related pathways identified using the gastric
tissue genes include Type II diabetes mellitus and Chagas
disease. Type II diabetes mellitus is known to increase the
risk of gastric cancer [83]. Chagas disease affects several
gastrointestinal regions, but there is no apparent relationship
with the growing incidence of cancer [84].

Thyroid
Using the thyroid tissue genes, we identified a
tyrosine metabolism pathway where the thyroid gland
uses tyrosine residues to generate T3 and T4, metabolic
hormones known to be involved in thyroid cancer [58, 59].

Signaling pathways
Signaling pathways controlling cell growth, cell
division, cell death, cell fate, and cell motility are almost
invariably altered in cancer [60]. Many of the signaling
pathways found in this study were identified using tissuespecific genes (discussed below).

Gene ontology functional analysis
A Gene Ontology-based similarity assessment indicates
that the selected genes for each tissue type are functionally
diverse, further validating our gene selection method.

Blood

Blood

The pathways identified using the blood tissue genes
are involved in intracellular signaling (Rap1 signaling,
NF-kappa B, and neuroactive ligand-receptor interaction
signaling). Ras is known to induce myeloproliferative
disorders and acute myeloid leukemia [61, 62]. Nuclear
factor-kappaB is constitutively activated in human acute
myeloid leukemia cells [63–68].

Many of the functional groups identified are known
to be involved in cancer. For example, protein-kinase
inhibitor activity (GO:0004860) and negative regulation of
JAK/STAT cascade (GO:0046426) groups were identified
using the blood tissue genes. Tyrosine kinase inhibitors
are known to be useful in the treatment of acute myeloid
leukemia [85]. The JAK/STAT signaling pathway is a
known target for the treatment of leukemia [86].

Gastric
Signaling pathways and interaction networks were
altered in gastric cancer tissues [69, 70]. The pathways
identified using the gastric tissue genes were involved in
signaling aparati (chemokine signaling, Ras signaling,
phosphatidylinositol signaling, PI3K-Akt signaling, sphingolipid
signaling, phototransduction, and cGMP-PKG signaling).
Phototransductive proteins are expressed to increase intracellular
calcium in tumor cells for gastric cancer patients [71, 72].

Breast
One of the many functional groups found by the
methods of this study was the breast-cancer gene list,
which includes the myosin complex (GO:0016459).
Myosin is known to promote breast cancer malignancy
by enhancing tumor cell proliferation [87]. Mutant p53associated motor protein myosin upregulation is known
to promote breast cancer invasiveness and metastasis
[88, 89]. Myosin light-chain kinase is known to play a role
in the proliferation and migration of breast cancer cells [90].

Head and neck
Most of the pathways identified using head and neck
genes are specific to cellular signaling and regulation of
signaling pathways known to be involved in head and neck
cancer, including complement and coagulation cascades,
signaling pathways regulating pluripotency of stem cells,
Ras signaling, PI3K-Akt signaling and RNA degradation.
Rap1 signaling, Rap1, and Rap1GAP are known to play a
role in the progression of squamous-cell carcinoma of the
head and neck. Rap-1A pathway is also associated with
survival, tumor progression, and metastasis of oral cavity
squamous cell carcinoma patients [73, 74].

Colon
A few of the many functional groups found using
our colon cancer gene list include the G-protein coupled
receptor signaling pathway (GO:0007186) and GTPase
activity (GO:0003924). G-protein coupled receptor
kinase-5 is known to regulate proliferation and chemokine
gene expression in human colon cancer epithelial cells
[91]. G-protein-coupled receptors for short-chain fatty
acids are known to suppress colon cancer [92]. GTPase
activation is known to be present in colon cancer [93].

Infectious disease-related pathways

Gastric

Many cancers have been attributed to infections
[75–77]. Cancers caused by infections are thought to result
www.impactjournals.com/oncotarget
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plants, is known to induce apoptosis in human gastriccancer cells [94].

[105]. A total of 2,175 tissue samples, both normal and
cancerous, were collected from nine distinct tissues:
blood (595), breast (171), colon (105), gastric (333),
head and neck (82), lung (542), prostate (56), thyroid
(224), and tongue (67). The detailed sample distribution
is shown in Figure 13, and Supplementary Table 16. The
accession numbers for the data are as follows: blood data:
GSE6891, GSE267, GSE43346, GSE63270; breast data:
GSE5460, GSE2361, GSE20437, GSE43346; colon data:
GSE64857, GSE4107, GSE2361, GSE43346; gastric
data, GSE2361, GSE43346, GSE19826, GSE62254,
GSE8167; head and neck data: GSE45153, GSE10300,
GSE43346, GSE8987; lung data: GSE1133, GSE10072,
GSE2361, GSE43346, GSE16538, GSE19804, GSE21369,
GSE24206, GSE63074; prostate data: GSE46602,
GSE6369, GSE1133, GSE2361, GSE43346; thyroid data:
GSE33630, GSE5054, GSE58545, GSE2361, GSE43346,
GSE60542, GSE3467, GSE3678, GSE35570; tongue data:
GSE52915, GSE9844, GSE1133, GSE43346. Samples used
in this study were collected directly from patients according
to experimental design. The frequency of data derived
from tissue samples was balanced across tissue classes and
entered into a composite data set. The data were collected
from the following three Affymetrix Human Genome: HGU133_Plus_2, HG-U133A, and HG-U133A_2.

Lung
Significant functional groups found using lung
tissue genes include the G-protein coupled receptor
signaling pathway (GO:0007187) and the regulation of
MAPK cascade (GO:0043408). The G protein-coupled
receptor is known to promote tumorigenesis and is
highly expressed in lung cancer [95]. Overexpression of
G protein-coupled receptors is known to correlate with
poorer tumor differentiation and higher tumor proliferation
in non-small-cell lung cancer [96]. Expression of MitogenActivated Protein Kinase is known to present in patients
with small cell lung cancer [97–100].

Biomarkers
Biomarkers can be used in clinical settings for patient
assessment, estimates of morbidity, screening for cancer,
distinguishing benign tissue from malignant tissue, and
determination of prognosis. The sensitivity and specificity of
biomarkers identified in this study exceeded those of known
biomarkers for all compared tissue types, suggesting that
these predicted biomarkers are robust indicators of cancer.
Further research may include the testing blood-based
biomarkers from the list of biomarkers under consideration
for this study. For example, blood-based biomarkers
have been used for diagnosis, prognosis and treatment of
colorectal cancer [7, 101], breast cancer [8, 102], prostate
cancer ([103], ovarian cancer [104], and lung cancer [9].
Machine learning cancer prediction models were
developed to identify potential biomarkers for unbiased
cancer diagnosis and effective treatment, ultimately improving
prognoses. Large publicly-available tissue-specific microarray
gene expression data were used for cancer type prediction,
as well as characterization of tissue-specific normal samples
into their various tissues of origin. A logical next step in this
work would be the application of machine learning to the
generation of a working model of both homeostatic and cancer
developmental processes for cancer biomarker detection
and early diagnosis. Such work would require collection of
numerous forms of data (such as methylation, metabolic and
even miRNA data) from a diverse panel of patients including
but not limited to, demographic information, normal tissue
controls, tumor characteristics, different forms of cancer,
subtypes of cancer, and perhaps even other inflammatory
diseases such as rheumatoid arthritis, from patients at varying
stages of disease progression and development.

Normalization and background correction
Normalization and preprocessing are essential
steps for the analyses of high-throughput data including
microarrays. The Affy R module 1.54 [106] from
Bioconductor package (https://bioconductor.org/packages/
release/bioc/html/affy.html) was used to remove the
technical variation from noisy data and background noise
from signal intensities. The Quantile Normalization Method
[107] was used to normalize the data, and the background
correction was performed using the Robust Multi-Average
(RMA) [108] parameter method. Quantile normalization
method relies on the assumption that observed global
changes across samples are due to unwanted technical
variability. We used quantile normalization since it is a
simple, fast, one-size-fits-all solution for transforming all
the arrays to have a common distribution of intensities.
The algorithm maps every value on any one chip to the
corresponding quantile of the standard distribution. The
intensities of all probes on each chip into one standard
distribution shape, which is determined by pooling all the
individual chip distributions. We used RMA because it
has a smaller standard deviation at all levels of expression
compared to dChip and MAS5.0 [108].

MATERIALS AND METHODS

Probe to gene mapping

Data collection

Using the information provided in Affymetrix
annotation files (http://www.affymetrix.com/support/
technical/annotationfilesmain.affx), probe names were
replaced with their respective gene names. Since multiple

Microarray gene expression data were collected
from NCBI Gene Expression Omnibus (GEO) repository
www.impactjournals.com/oncotarget

85707

Oncotarget

probes can also correspond to the same gene, the expression
values for duplicate entries were averaged within samples.
All preprocessed data were randomly divided into equalsized subsets of training and testing datasets. Since the
datasets are unbalanced across classes, class distributions
are approximately preserved for each tissue using stratified
partitioning for training and testing sets.

Ranker, SymmetricalUncertAttributeEval_Ranker, Wrapper
SubsetEval_GeneticSearch) and 13 feature thresholds (Top
1%, 2%, 3%, 4%, 5%, 10%, 20%, 25%, 33%, 50%, 66%,
75%, 100%) is shown.

Machine learning classification model construction
Machine learning classification models can be
categorized into the following four groups: (1) models
which, given a sample of a specific tissue type, classify the
sample as cancer or normal (“single-tissue”), (2) models
which, given a sample of any of the nine tissue types,
classify the sample as cancer or normal (“multi-tissue biclass”) (3) models which, given a sample of any of the
nine tissue types, classifies the sample as cancer or normal
and as of a specific tissue type (“multi-tissue multi-class”)
and (4) a model which, given a normal sample of any of
the nine tissue types, classifies the sample as of a particular
tissue type (“multi-tissue normal multi-class”). (See
Figure 13A and Supplementary Table 17 for distribution
of samples among tissue types). The overall workflow of
the model construction is given in Figure 14. Models were
constructed using Random Forests and Support Vector
Machine. The configurable CancerDiscover software
pipeline [113] was used to perform all the machine
learning steps in this study.

Identification of best feature selection algorithm
The key to construction of accurate and
unbiased machine learning models from microarray
gene expression data is identification of the features
(genes) best able to predict tissue class and cancer
status [109]. The test set must be kept separate from
the model training set Support Vector Machine (SVM)
[110], IBk K-nearest neighbor [111], and Naive Bayes
[112] were used to identify the best feature selection
algorithm. The following 12 feature selection algorithms
were used to create the models: (Chi Squared_Ranker,
ClassifierSubsetEvaluator_GeneticSearch,ConsistencySub
setEvaluator_BestFirst, ConsistencySubsetEvaluator_Geneti
cSearch,ConsistencySubsetEvaluator_LinearFWDSelection,
FilteredAttributeEvaluator_Ranker,
GainRatioAttribute
Evaluator_Ranker, LatentSemanticAnalysis_Ranker, One
RAttributeEvaluator_Ranker, ReliefFAttributeEvaluator_

Figure 14: Types of machine learning classification model construction with the model name, the total number of
models, the number of classes, and disease states of sample source for each model type. Green box: unlabeled data; blue box:
cancer label; yellow box: normal label; BlC: blood-cancer, BlN: blood-normal, BrC: breast-cancer, BrN: breast-normal, CoC: colon-cancer,
CoN: colon-normal, GaC: gastric-cancer, GaN: gastric-normal, HeC: head and neck-cancer, HeN: head and neck-normal, LuC: lung-cancer, LuN:
lung-normal, PrC: prostate-cancer, PrN: prostate-normal, ThC: thyroid-cancer, ThN: thyroid-normal, ToC: tongue-cancer, ToN: tongue-normal.
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Machine learning algorithms and framework

TP + TN
TP + TN + FP + FN
TP
Recall / Sensitivity =
TP + FN
TN
Specificity =
TN + FP
TP
Precision =
TP + FP
Precision * Recall
F1 − Score =
2*
Precision + Recall
Accuracy =

Support Vector Machines (SVMs) and Random
Forests were used to construct the models for this study.
These machine-learning methods were chosen because
of their extensive and successful applications to datasets
from genomic and proteomic domains [114, 115]. Some of
the cancer classification tasks were binary (two classes),
and the others were multiclass (more than two classes).
Though SVMs are designed for binary classification,
they can also be used for multiclass classification by
a one-versus-rest approach [116]. The one-versus-rest
approach for classification is known to be among the
best-performing methods for multicategory classification
for microarray gene expression [30]. Models were also
constructed using Random Forests (RF), which can
solve multicategory problems natively through direct
application.
The Random Forests algorithm is well suited to the
classification of genomic data because of the following
advantages (i) it performs embedded feature selection
(ii) it incorporates interactions between predictors: (iii)
it allows the algorithm to accurately learn both simple
and complex classification functions; (iv) it is applicable
to both binary and multicategory classification tasks
[117]. Feature selection and model construction was also
accomplished using WEKA (Waikato Environment for
Knowledge Analysis) [118] version 3.8.

Model selection and accuracy estimation
For model selection and accuracy estimation, we
used 10-fold cross-validation [30, 115]. This technique
separates data into ten parts and uses nine parts for the
model generation while predictions are generated and
evaluated by using the one part. This step is subsequently
repeated ten times, so each part (internal test set) is tested
against the other nine parts (internal train set). The average
performance over the ten accuracies is accepted as an
unbiased estimate of the model’s performance.

Functional analysis
We used Database for Annotation, Visualization, and
Integrated Discovery (DAVID) v6.8 [119] for functional
analysis. For each of the nine tissue type provided to
DAVID, the tissue-specific gene list consisting of top
244 (1%) of genes were used to classify samples of a
particular tissue type as either cancerous or normal (See
Supplementary File 2). Within DAVID, KEGG was chosen
for pathway analysis. Of the pathways returned, only those
with a p-value of less than or equal to 0.05 and with three
or more of our genes were considered. Within DAVID,
Functional Annotation analysis was used for sorting the
genes according to functional groups. Of the functional
groups returned, only those with a p-value of less than or
equal to 0.05 and with three or more of the genes identified
in this study were considered.

Measures
Accuracy was defined as the overall ability of
models to categorize testing sample data correctly.
Reported measures included the numbers of true positives
(TP), true negatives (TN), false positives (FP), and false
negatives (FN). A true-positive count is the number of
samples in a dataset which were correctly categorized into
classes. A false-positive count is the number of samples
in a dataset which were sorted into the wrong category.
A true negative count represents the number of samples
which were not classified into a class to which they do
not belong, and false negatives are samples which are not
classified into the class to which they do belong.
Accuracy, Sensitivity (or Recall), Specificity, Precision,
and F1-score are derived from the measures mentioned above
as follows: accuracy is the ratio of correctly predicted samples
to the total number of samples. Sensitivity is the proportion
of true positives that are predicted as positives. Specificity
is the proportion of true negatives which are predicted as
negatives, and Precision is the ratio of true positives to the
total number of true negatives and true positives. Lastly,
F1-score is defined as the harmonic mean of Precision and
Recall and is calculated by first multiplying precision and
recall values, then dividing the resulting value by the total
of precision and recall, and finally, multiplying the result by
two. The Accuracy, Sensitivity, Specificity, Precision, and F1Score are given by:
www.impactjournals.com/oncotarget
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